Latest Biotech News

Daewoong Pharmaceutical secured an exclusive license to Innovo Therapeutics’ INV-008 in a deal potentially valued at about ₩662.5 billion (US$443.6 million), the companies said. The licensed...

Personalis shares rose after the Centers for Medicare and Medicaid Services expanded coverage for its NeXT Personal minimal residual disease assay. The MolDX program expanded reimbursement to...

BioMarin began workforce consolidation at Amicus’ headquarters in Princeton, New Jersey after completing its $4.8 billion acquisition of Amicus Therapeutics for rare disease medicines. A WARN...

Isomorphic Labs closed a $2.1 billion Series B round, reinforcing investor backing for its AI-first approach to drug discovery. Thrive Capital led the round, joined by Alphabet and Google’s GV,...

New trial results published in medical journals suggest obesity weight loss can be maintained by shifting from higher-dose injectables to lower doses or switching to oral formulations. The updates...

LiquidCell Dx announced development of a liquid-biopsy platform, LiquidTME, designed to predict response to immune checkpoint inhibitors by profiling tumor microenvironment ecosystems. The startup...

Seer filed a patent infringement lawsuit against Nanomics Biotechnology, asserting multiple patents covering Seer’s nanoparticle-based protein enrichment technology used in its Proteograph product...

Encoded Therapeutics’ Dravet syndrome gene regulation program ETX101 is reporting updated clinical data showing dose-dependent seizure reduction through 52 weeks in a Phase I/II setting, according...

BioMarin said it is integrating Amicus Therapeutics after closing its $4.8 billion acquisition and plans layoffs tied to overlapping functions at the Amicus headquarters in Princeton, New Jersey....

Isomorphic Labs, the Alphabet/Google-backed AI drug discovery firm, closed a $2.1 billion Series B round to scale its drug design platform and accelerate internal pipeline candidates toward...

Bristol Myers Squibb and Hengrui Pharma entered a broad 13-program research pact spanning oncology, hematology, and immunology, with deal value potentially reaching $15.2 billion. BMS will pay...

Roche moved to tighten its oncology diagnostics playbook with two pending acquisitions and a sequencing platform launch schedule outlined at its Diagnostics Day. The company said it will acquire...

Encoded Therapeutics presented trial findings tied to steroid and sirolimus use designed to manage immune responses in an AAV9-based gene therapy program for Dravet syndrome. In a subset of...

Kyverna Therapeutics began a rolling submission to the FDA for miv-cel, aiming to position the candidate as the first autoimmune CAR-T therapy to reach the market. The company said it is...

Clinical data from the MYTHIC trial showed activity for lunresertib plus zedoresertib in platinum-resistant ovarian cancer, including higher response rates in the CCNE1-amplified subgroup. At the...

ICON opened a new Clinical Research Unit in San Antonio, Texas, expanding its early-phase capabilities for first-in-human and healthy participant studies. The facility integrates clinical,...

Parexel acquired Vitrana, an AI-focused pharmacovigilance technology provider, to automate and streamline drug safety case processing for clinical trial programs. Parexel said the acquisition...

Marty Makary resigned as FDA commissioner, ending a contentious tenure that included frequent leadership turnover and shifting guidance dynamics for regulated companies. President Trump confirmed...

Isomorphic Labs closed a $2.1 billion Series B to scale its unified AI drug design engine and advance programs into clinical development, the company said. The round—reportedly among the largest...

Bristol Myers Squibb and Hengrui Pharma signed a global drug research pact spanning 13 programs across oncology, hematology and immunology, with $600 million upfront and up to $15.2 billion in...